Journal ArticleDOI
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
Reads0
Chats0
TLDR
In this paper, a review summarizes the pathophysiology of major depressive disorder found in the glutamate system, exploring the role of glutamate receptors and their downstream effects, and further insight into the mechanism of depression and exploring potential targets for novel agent development.About:
This article is published in Pharmacological Research.The article was published on 2021-09-01. It has received 15 citations till now. The article focuses on the topics: Metabotropic glutamate receptor & Glutamatergic.read more
Citations
More filters
Journal ArticleDOI
Paeoniflorin: A neuroprotective monoterpenoid glycoside with promising anti-depressive properties.
TL;DR: Wang et al. as mentioned in this paper summarized the effective anti-depressive properties of paeoniflorin, which is related to its functions in the upregulation of the levels of monoaminergic neurotransmitters, inhibition of the hypothalamic-pituitary-adrenal axis hyperfunction, promotion of neuroprotection, and promotion of hippocampus neurogenesis.
Journal ArticleDOI
Melatonin: From Neurobiology to Treatment.
Giovanni Biggio,Francesca Biggio,Giuseppe Talani,Maria Cristina Mostallino,Andrea Aguglia,Eugenio Aguglia,Laura Palagini +6 more
TL;DR: These properties of melatonin have allowed us to demonstrate in both experimental models and clinical studies the great chronobiotic efficacy and sleep promoting effects of exogenous melatonin.
Journal ArticleDOI
Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.
Ya-Ting Wang,Ning-ning Zhang,Ling Liu,Hong Jiang,Die Hu,Zhen-Zhen Wang,Nai-Hong Chen,Yi Zhang +7 more
TL;DR: In this paper , the convergent downstream pathways of ketamine and rapastinel were explored and further development of identification for following generational rapid-acting antidepressants in the synaptic process was proposed.
Journal ArticleDOI
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
TL;DR: The mechanism of action of these compounds suggests a strong glutamatergic component that involves the facilitation of AMPA receptor function, which appears to be relevant to the antidepressant pharmacology of this new class of drugs.
References
More filters
Journal ArticleDOI
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
Ronald C. Kessler,Patricia A. Berglund,Olga Demler,Robert Jin,Doreen S. Koretz,Kathleen R. Merikangas,A. John Rush,Ellen E. Walters,Philip S. Wang +8 more
TL;DR: Notably, major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment, and while the recent increase in treatment is encouraging, inadequate treatment is a serious concern.
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
Selective impairment of learning and blockade of long-term potentiation by an N -methyl-D-aspartate receptor antagonist, AP5
TL;DR: This article showed that chronic intraventricular infusion of D,L-AP5 causes a selective impairment of place learning, which is highly sensitive to hippocampal damage, without affecting visual discrimination learning.
Journal ArticleDOI
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
John H. Krystal,Laurence P. Karper,John Seibyl,Glenna K. Freeman,Richard C. Delaney,J. Douglas Bremner,George R. Heninger,Malcolm B. Bowers,Dennis S. Charney +8 more
TL;DR: These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.